MDD among adolescents represents a critical public health challenge with significant long-term implications. The past three years have witnessed a substantial 30% growth in industry-sponsored clinical studies focused on depression, highlighting an increasing research commitment to mental health interventions. The market for MDD is expected to exceed $19 billion by 2030.
Cambridge Cognition has been selected as a strategic partner to advance clinical trial methodologies through innovative speech analysis. By integrating speech biomarkers with cognitive assessments, the platform enables more precise patient monitoring, allowing researchers to capture nuanced treatment-response insights. Additionally, the inclusion of cognitive assessments will enable detection of improvements in cognitive function, which is frequently impaired in depression and closely linked to overall functioning.
Rob Baker, Joint Managing Director and Chief Operating Officer, commented:
“This strategically important contract win highlights the value of our integrated speech and cognitive platform that not only delivers robust and reliable results for the pharmaceutical company but also reduces trial costs and patient burden. As a result, we see significant future demand for our unique platform, and we remain confident in our ambitions to significantly grow sales in the high-impact, late-stage CNS trials market over the coming years.”
- Thapar, A., Collishaw, S., Pine, D. S., & Thapar, A. K. (2012). Depression in adolescence. The Lancet, 379(9820), 1056-1067.
- Data sourced from Citeline’s Trial Trove, Informa Pharma Intelligence, accessed March 2025
- Anxiety Disorders And Depression Treatment Market Size, Share & Trends Analysis Report By Drug Type, By Indication (Depression, Anxiety), By Distribution Channel, By Region, And Segment Forecasts, 2025 – 2030. Grand View Research
